a b s t r a c t l-Opioids remain vastly important for the treatment of pain, and would represent ideal analgesics if their analgesic effects could be separated from their many side effects. A recently synthesized compound, iodobenzoylnaltrexamide (IBNtxA), acting at 6-transmembrane (6-TM) splice variants of the l-opioid receptor gene, was shown to have potent analgesic actions against acute, thermal pain accompanied by a vastly improved side-effect profile compared to 7-TM-acting drugs such as morphine. Whether such analgesia can be seen in longer-lasting and nonthermal algesiometric assays is not known. The current study demonstrates potent and efficacious IBNtxA inhibition of a wide variety of assays, including inflammatory and neuropathic hypersensitivity and spontaneous pain. We further demonstrate the dependence of such analgesia on 6-TM l-opioid receptor variants using isobolographic analysis and the testing of Oprm1 (the l-opioid receptor gene) exon 11 null mutant mice. Finally, the effect of nerve damage (spared nerve injury) and inflammatory injury (complete Freund's adjuvant) on expression of l-opioid receptor variant genes in pain-relevant central nervous system loci was examined, revealing a downregulation of the mMOR-1D splice variant in the dorsal root ganglion after spared nerve injury. These findings are supportive of the potential value of 6-TM-acting drugs as novel analgesics. Ó
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Introduction
Opioids remain the gold standard for the treatment of moderate-to-severe pain, with an increase in opioid prescriptions for chronic pain in recent years [5] . Despite their high efficacy in the context of acute pain, opioids are associated with a number of troubling side effects, including respiratory depression, reduced gastric motility, and dependence/addiction [2] . As a result, a major goal of pain research is to identify compounds with similar efficacy but fewer liabilities.
Three opioid receptor genes are known, and the vast majority of current opioid analgesics bind to and activate the l-opioid receptor [12], a 7-transmembrane (7-TM) G-protein-coupled receptor.
Cloning of the l-opioid receptor gene (OPRM1) has demonstrated its high complexity, comprising a wide array of mRNA splice variants [18] . These splice variants can subsequently be grouped into those coding for full-length, 7-TM proteins, truncated 6-transmembrane (6-TM) proteins, and finally single transmembrane (1-TM) proteins [21, 28, 30] . Recently, we demonstrated that 3-iodo-6b-benzoylnaltrexamide (IBNtxA), a naltrexone derivative, acting on 6-TM alternative splice variants of the mouse Oprm1 gene, produces analgesia against acute, thermal pain $10-fold more potently than morphine, without evidence of respiratory depression, significant constipation, reward, aversion, or dependence (as evidenced by precipitated withdrawal) [11] . Although these assays (ie, hot-plate and tail-withdrawal tests) have historically been predictive of clinical opioid efficacy against somatic pain, they are highly limited in their prediction of efficacy against inflammatory and neuropathic pain, leading to the development of many new assays in modern pain research [13] . Thus, one purpose of the current work was to test the analgesic potential of IBNtxA in more clinically relevant chronic inflammatory (zymosan, complete Freund's adjuvant) and neuropathic (spared nerve injury) assays, and using multiple measures of different pain modalities (thermal, mechanical 
